Palatin Technologies (PTN) Share-based Compensation (2010 - 2026)
Palatin Technologies' (PTN) quarterly Share-based Compensation came in at $419968.0 in Q1 2026, up 20.79% on a YoY basis from $347691.0 in Q1 2025, and up 35.15% quarter-over-quarter from $310739.0 in Q4 2025.
Analysis
Palatin Technologies (PTN) Share-based Compensation (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Share-based Compensation for 17 consecutive years, with $419968.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 20.79% year-over-year to $419968.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 22.22% YoY), and the FY2025 full-year result was $1.4 million, down 26.19% from the prior year.
- Share-based Compensation climbed to $419968.0 in Q1 2026 per PTN's latest filing, from $310739.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $21.7 million in Q1 2022 and bottomed at $167711.0 in Q3 2025.
- Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $390336.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation tumbled 95.92% in 2023, then jumped 144.23% in 2024.
- Over 5 years, Share-based Compensation stood at $887395.0 in 2022, then sank by 38.02% to $549971.0 in 2023, then sank by 36.55% to $348955.0 in 2024, then declined by 10.95% to $310739.0 in 2025, then soared by 35.15% to $419968.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $419968.0, $310739.0, and $167711.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 419,968.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 419,968.00 |
| Dec 31, 2025 | 310,739.00 |
| Sep 30, 2025 | 167,711.00 |
| Jun 30, 2025 | 336,612.00 |
| Mar 31, 2025 | 347,691.00 |
| Dec 31, 2024 | 348,955.00 |
| Sep 30, 2024 | 349,023.00 |
| Jun 30, 2024 | 542,196.00 |
| Mar 31, 2024 | 390,195.00 |
| Dec 31, 2023 | 549,971.00 |
| Sep 30, 2023 | 390,336.00 |
| Jun 30, 2023 | 221,999.00 |
| Mar 31, 2023 | 884,408.00 |
| Dec 31, 2022 | 887,395.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 715,591.00 |
| Mar 31, 2022 | 21.69 Mn |
| Dec 31, 2021 | 21.75 Mn |
| Sep 30, 2021 | 21.82 Mn |
| Jun 30, 2021 | 709,494.00 |